Lv65
2790 积分 2024-12-03 加入
Therapeutic Potential of Tulisokibart and Anti-TL1A Therapy in Inflammatory Disorders: Current Insights and Future Directions
2天前
已完结
Review Article: TL1A Inhibitors in IBD ‐ Mechanistic Rationale and Clinical Evidence
2天前
已完结
T cell engagers in autoimmune diseases
20天前
已完结
Conditionally Activatable Antibody Platforms: Mechanisms, Modalities, and Clinical Translation Potential
28天前
已完结
T-cell engagers in rheumatology
3个月前
已关闭
Immune mediated inflammatory disease: T cell engager versus antibody drug conjugate
3个月前
已完结
Bispecific T-cell engagers in autoimmune diseases: mechanisms of action, clinical evidence challenges, and therapeutic perspectives
3个月前
已完结
Therapeutic Potential of Tulisokibart and Anti-TL1A Therapy in Inflammatory Disorders: Current Insights and Future Directions
3个月前
已完结
Review Article: TL1A Inhibitors in IBD ‐ Mechanistic Rationale and Clinical Evidence
3个月前
已完结
Mechanisms for resistance to BCMA-targeted immunotherapies in multiple myeloma
4个月前
已完结
皖公网安备34019202002308
